The Filing Desk

PetMed Express

PETS · Nasdaq · Consumer Discretionary · Financials, fiscal 2017 to 2026

PETS · Last close · November 19, 2026
$0.92
Value PetMed Express yourself

PetMed Express' revenue fell 21.1% to $179 million in fiscal 2026. Its operating margin was −32.8%, down from −0.7% a year earlier. Free cash flow was −$33 million. It paid out $0 million in dividends and buybacks. The diluted share count rose 1.6%.

PETMED EXPRESS, INC. Latest fiscal year ended March 31, 2026 10-K filed June 2, 2026 · 0001040130-26-000019 Updated
Revenue
$179M
21.1%
Operating margin
−32.8%
32.1 pts
Net income
−$57M
 
Free cash flow
−$33M
 
Return on equity
−100.4%
93.5 pts
Market cap
$20M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2023, earnings per share fell 22.7% a year and net income 22.6% a year, with the share count about the same. PetMed Express then lost money in fiscal 2024, 2025 and 2026.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments111104555521
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio2.7x2.3x1.3x1.3x0.8x
Quick ratio2.1x1.9x0.9x1.0x0.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project PetMed Express' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $43,750 of PetMed Express shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jun 8, 2026Zyman Stephannie Matz10% ownerBought25,000$1.75$43,750Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score———
Rule of 4010.6%−17.4%−39.6%
Altman Z''3.273.51−4.59
Accruals ratio−7.0%−6.9%−25.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailFail
Cash from operations is positivePassPassFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put PetMed Express side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PetMed ExpressFY26−21.1%−32.8%−18.4%———
GrowGenerationFY25−14.4%−15.8%—−35.1%—5Compare
EnvelaFY2533.6%7.5%0.6%27.1%−0.4x6Compare
ThredUpFY2519.5%−7.0%0.1%−54.2%—4Compare
Rent the RunwayFY257.7%−17.4%−21.9%−77.8%—6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue249274283284304272248274227179
Revenue growth6.2%9.9%3.5%0.2%6.8%−10.3%−9.1%10.7%−17.2%−21.1%
Gross profit79989581847776856950
Research and development——————————
Operating income3852463130246−8−2−59
Net income2437382624195−8−6−57
Diluted EPS (US$)1.171.821.841.291.190.920.25−0.37−0.30−2.74
Diluted shares (millions)20202020202020202121
Cash flow
Cash from operations4737453940182845−28
Capital expenditure11112225455
Free cash flow37374537381723−0−0−33
Dividends paid161822222324241200
Share buybacks00012000000
Acquisitions00000003600
Stock-based compensation23333477−71
Balance sheet at fiscal year end
Cash and short-term investments5978100104119111104555521
Debt incl. finance leases——————————
Total assets11313515415518818016817014981
Total liabilities19192025465658736452
Shareholders' equity93116135120125123110978529
Margins and ratios
Gross margin31.8%35.7%33.6%28.6%27.8%28.3%30.9%30.9%30.5%28.1%
Operating margin15.0%19.0%16.3%10.9%10.1%8.9%2.4%−3.0%−0.7%−32.8%
Net margin9.6%13.6%13.3%9.1%7.9%6.9%2.1%−2.7%−2.8%−32.0%
Free cash flow margin14.7%13.4%15.7%12.9%12.4%6.2%9.1%−0.1%−0.2%−18.4%
Rule of 40 (growth + FCF margin)20.9%23.3%19.2%13.1%19.2%−4.2%0.0%10.6%−17.4%−39.6%
Return on capital——————————
Return on equity27.0%35.7%30.1%20.3%19.5%15.1%4.4%−7.2%−6.9%−100.4%
Return on assets23.5%30.1%26.1%16.7%13.9%10.2%3.0%−4.4%−3.9%−49.8%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: PetMed Express' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with PetMed Express.